NEW YORK — Lab Genomics has signed a distribution agreement to offer Contextual Genomics' Follow It next-generation sequencing-based cancer genomic assay in Southern California and certain other parts of the US, the companies announced on Monday.
Specific terms of the deal were not disclosed.
Follow It screens for cell-free circulating tumor DNA in plasma to identify somatic genome alterations that can be used to guide treatment selection and recognize acquired drug resistance mutations. The assay was launched last month.
In late 2017, Vancouver, Canada-based Contextual signed a Brazilain distribution deal for its Find It solid tumor test with Idengene. That same year, Sonic Healthcare began offering Find It through its labs in Australia and other countries.